Groupe la Francaise Buys 10,556 Shares of Abbott Laboratories $ABT

Groupe la Francaise increased its stake in Abbott Laboratories (NYSE:ABT) by 22.3% during the second quarter, Holdings Channel reports. The firm owned 57,813 shares of the healthcare product maker’s stock after acquiring an additional 10,556 shares during the period. Groupe la Francaise’s holdings in Abbott Laboratories were worth $5,248,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABT. California State Teachers Retirement System grew its stake in Abbott Laboratories by 9,127.1% during the second quarter. California State Teachers Retirement System now owns 246,828,861 shares of the healthcare product maker’s stock worth $22,397,251,000 after buying an additional 244,153,804 shares in the last quarter. J. Stern & Co. LLP raised its stake in Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Norges Bank acquired a new position in shares of Abbott Laboratories during the fourth quarter worth $2,938,892,000. Bank of America Corp DE acquired a new position in Abbott Laboratories in the 2nd quarter worth about $1,603,607,000. Finally, Legal & General Group Plc acquired a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $1,082,524,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on ABT. Royal Bank Of Canada reiterated an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Citigroup increased their price target on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. UBS Group decreased their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. TD Cowen upped their price objective on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Finally, BTIG Research lifted their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Trading Down 0.0%

Shares of Abbott Laboratories stock opened at $108.29 on Tuesday. The company has a 50 day simple moving average of $104.74 and a two-hundred day simple moving average of $100.00. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a market cap of $187.38 billion, a PE ratio of 35.05, a PEG ratio of 2.01 and a beta of 0.59. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same period in the previous year, the business earned $1.26 earnings per share. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.